Akums Drugs & Pharmaceuticals Limited has announced its financial results for the second quarter of FY27, ending September 30, 2026. The company reported a consolidated revenue of INR1,342 crores, marking a significant 31.9% increase year-on-year. EBITDA also saw a substantial jump of 106% year-on-year, reaching INR195 crores. This strong performance was driven by double-digit volume growth across its segments, particularly in the CDMO business.
Akums Drugs & Pharmaceuticals Q2 FY27 Earnings Highlights
Akums Drugs & Pharmaceuticals Limited announced its financial results for the second quarter and half year ended September 30, 2026. The company showcased a strong performance, with consolidated revenue standing at INR1,342 crores. This represents a significant year-on-year increase of 31.9%, compared to INR1,018 crores in Q2 FY26. Quarter-on-quarter, revenue grew by 15.1% from INR1,167 crores in Q1 FY27.
EBITDA and Profitability Surge
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) for the quarter were robust at INR195 crores, a substantial increase of 106% year-on-year from INR94 crores in Q2 FY26. Sequentially, EBITDA grew by 11.5% from INR175 crores in Q1 FY27. The company maintained healthy margins at 14.5%, up from 9.3% in Q2 FY26 and 15% in Q1 FY27. Profit after tax stood at INR115 crores, an increase of 168.3% year-on-year.
Segment-wise Performance
The Contract Development and Manufacturing Organization (CDMO) segment was a key driver of growth, reporting revenue of INR1,115 crores, an increase of 38.6% year-on-year and 15.6% quarter-on-quarter. EBITDA for this segment grew by 99.6% year-on-year to INR168 crores.
The domestic branded formulations segment recorded revenue of INR132 crores, an 8.2% increase year-on-year, with EBITDA at INR24 crores. International branded formulations revenue surged by 95.2% year-on-year to INR44 crores, with EBITDA reaching INR9.9 crores.
The API segment saw revenue of INR29 crores, a decrease of 35.3% year-on-year, with an EBITDA loss of INR5.7 crores. The trade generics business reported revenue of INR23 crores and EBITDA of INR1.2 crores.
Strategic Initiatives and Outlook
During the quarter, Akums successfully integrated two manufacturing plants acquired from Oriflame, strengthening its position in the beauty and personal care sector. The company also announced plans to operationalize a new facility at Baddi. Investments are being made in R&D, with approximately 3% of CDMO revenues allocated to developing new products and quality pipeline assets.
The company is focused on geographical diversification and expanding its global footprint, with plans for European and Zambian business ventures progressing. The balance sheet remains healthy, with cash and cash equivalents at INR1,680 crores and a free cash flow of INR45.5 crores for H1 FY27.
Source: BSE
